France lists more innovative/costly device to be paid from separate budgets:
This article was originally published in Clinica
Executive Summary
Two decrees have been published in the French Journal officiel in November determining medical devices that will be paid for in France over and above the standard stay group tariffs (GHS - a single tariff payment by the government to cover the costs of an entire medical procedure). Products that will be paid for separately, as listed in the decrees published on November 22 and November 1, are certain types of the following: urogenital implants; heart valves; defibrillators; vascular implants; and pacemakers. Industry had lobbied successfully for some of the more costly or innovative products to be paid for separately from the GHS, as it feared that hospitals would otherwise be unable to meet the costs of such products from already-squeezed diagnosis-related group style budgets.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.